Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   127 Trials   127 Trials   2574 News 


«12...1415161718192021222324...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Metastases:  TAS-102 in Treating Advanced Biliary Tract Cancers (clinicaltrials.gov) -  Oct 25, 2021   
    P2,  N=28, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Clinical, Journal:  A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer (Pubmed Central) -  Oct 22, 2021   
    Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered. In our case, starting at a low dose resulted in fewer adverse events, adequate disease control, and long-term administration.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial primary completion date:  MOCHA: Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (clinicaltrials.gov) -  Oct 21, 2021   
    P2,  N=47, Recruiting, 
    In our case, starting at a low dose resulted in fewer adverse events, adequate disease control, and long-term administration. Trial primary completion date: Sep 2021 --> Dec 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Long term survival (LTS) in metastatic gastrointestinal cancer and the relevance of the antiangiogenetic treatment () -  Oct 7, 2021 - Abstract #DGHO2021DGHO_944;    
    This effect is visible in the results of an adjuvant treatment following curative tumor resection and in the palliative setting when an additional and continuing antiangiogenetic treatment results in a significantly prolonged survival time. The efficacy of the antiangionetic treatment underlines the importance of endothelial cells and macrophages as protumoral acting elements in certain stages of the tumor growth.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Y not Lonsurf?? (Twitter) -  Oct 2, 2021   
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open, Minimal residual disease, Circulating tumor DNA:  Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas (clinicaltrials.gov) -  Sep 30, 2021   
    P2,  N=22, Recruiting, 
    Taken together, the results of the present study suggest that grade 3 or 4 CIN within the first cycle of treatment are early predictors of the efficacy of FTD/TPI + Bev. Not yet recruiting --> Recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Clinical, Journal:  Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. (Pubmed Central) -  Sep 29, 2021   
    Grade ≥ 3 toxicities were reported in 141 (37.2%) patients, including mainly afebrile neutropaenia (23.2%), anaemia (12.1%), and thrombocytopaenia (5.3%). This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date, Circulating tumor DNA, Metastases:  TACT-D: Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 28, 2021   
    P2,  N=100, Recruiting, 
    This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers. Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  Avastin (bevacizumab) / Roche
    Patients with RAS-mutated metastatic colorectal carcinoma - data from the clinical routine of over 1000 patients from the Colorectal Carcinoma (TKK) tumor registry (A7) -  Sep 20, 2021 - Abstract #DGHO2021DGHO_294;    
    Guidelines recommend chemotherapy (CT; fluoropyrimidine, irinotecan, oxaliplatin) with or without anti-angiogenic agents for two treatment lines...Between 2010 and 2018, pts with (K) RAS mut mCRC were mostly treated with a doublet CT and bevacizumab (BEV) as 1 st -line therapy, with the most frequent treatment regimens being FOLFIRI + BEV (30%), FOLFOX + BEV (25%), FOLFOX (13%) and FOLFIRI (9%)...The percentage of pts receiving 3 rd -line trifluridine / tipiracil increased over time from 9% in 2016 to 38% in 2019. This analysis of the RAS mut mCRC population enrolled prospectively in the TKK database provides important insights into treatment patterns, sequential treatments, and outcome of patients with RAS mut mCRC in routine clinical practice in Germany.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open, Trial primary completion date:  Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients (clinicaltrials.gov) -  Sep 20, 2021   
    P2,  N=49, Recruiting, 
    This analysis of the RAS mut mCRC population enrolled prospectively in the TKK database provides important insights into treatment patterns, sequential treatments, and outcome of patients with RAS mut mCRC in routine clinical practice in Germany. Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2024 --> Sep 2025
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE (clinicaltrials.gov) -  Sep 17, 2021   
    P1,  N=44, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2024 --> Sep 2025 Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Review, Journal:  Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. (Pubmed Central) -  Sep 8, 2021   
    High-quality evidence is limited, but this strategy is often used in routine clinical practice in the absence of alternative therapies especially in patients with good performance status. (4) To use specific treatments for very selected populations, such as trastuzumab/lapatinib in mCRC human epidermal growth factor receptor 2-positive, immunotherapy in microsatellite instability, intrahepatic therapies in limited disease or primarily located in the liver, although the main recommendation is to include patients in clinical trials.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
    Enrollment closed, Metastases:  RE-ExPEL: Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (clinicaltrials.gov) -  Sep 8, 2021   
    P=N/A,  N=20, Active, not recruiting, 
    (4) To use specific treatments for very selected populations, such as trastuzumab/lapatinib in mCRC human epidermal growth factor receptor 2-positive, immunotherapy in microsatellite instability, intrahepatic therapies in limited disease or primarily located in the liver, although the main recommendation is to include patients in clinical trials. Recruiting --> Active, not recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Focus V (anlotinib) / Advenchen, Sino Biopharm
    New P2 trial, Metastases:  TAS-102 and Anlotinib in ?3 Lines mGC (clinicaltrials.gov) -  Aug 30, 2021   
    P2,  N=45, Recruiting, 
  • ||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
    Enrollment open:  INTEGRATEIIb: RegoNivo vs Standard of Care Chemotherapy in AGOC (clinicaltrials.gov) -  Aug 30, 2021   
    P3,  N=450, Recruiting, 
    Further evaluation of the efficacy of this regimen is warranted. Not yet recruiting --> Recruiting
  • ||||||||||  Tirazone (tirapazamine) / Teclison, SRI International
    Enrollment open, Metastases:  KEYNOTE-A91: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC (clinicaltrials.gov) -  Aug 25, 2021   
    P2,  N=60, Recruiting, 
    Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Journal:  DNA replication stress induced by trifluridine determines tumor cell fate according to p53 status. (Pubmed Central) -  Aug 12, 2021   
    Here, we show that the fluorinated thymidine analogue trifluridine (FTD), an active component of the chemotherapeutic drug trifluridine/tipiracil, delayed DNA synthesis by human replicative DNA polymerases by acting both as an inefficient deoxyribonucleotide triphosphate source (FTD triphosphate) and as an obstacle base (trifluorothymine) in the template DNA strand, which caused DRS...These results demonstrate that DRS induced by a nucleoside analog-type chemotherapeutic drug suppresses tumor growth irrespective of p53 status by directing tumor cell fate toward cellular senescence or apoptotic cell death according to p53 status. Implications: Chemotherapeutic drugs that increase DRS during S phase but allow tumor cells to complete S phase may have significant anti-tumor activity even when functional p53 is lost.
  • ||||||||||  Yutuo (zimberelimab) / Arcus Biosci, Gilead
    New P1 trial, Metastases:  AB122 Platform Study (clinicaltrials.gov) -  Aug 10, 2021   
    P1,  N=170, Recruiting, 
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment change:  A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC (clinicaltrials.gov) -  Jul 26, 2021   
    P2,  N=18, Completed, 
    Patients with refractory MSS metastatic CRC failed to experience clinical benefit with FTD/TPI plus nivolumab, although safety data in this population indicated tolerability and feasibility of this combination. N=35 --> 18